Massachusetts hospital halts trans care due to funding threats from Trump

Massachusetts Health System Halts Transgender Hormone Treatment for Minors

A prominent medical organization in Massachusetts has decided to stop administering transgender hormone therapies to minors. This decision stems from concerns regarding the potential risk to federal funding, particularly amidst increased scrutiny from the Trump administration.

Baystate Health, which is the largest health provider in Western Massachusetts, has announced it will no longer provide puberty blockers or cross-sex hormones to individuals under 18. This move aligns with similar actions taken by other medical institutions that have reduced their transgender health services.

Reports indicate that Baystate Health sent out notifications about these changes to patients and their families on February 9. The health system emphasized that this decision aims to provide patients with continuous care while navigating a changing regulatory environment that poses threats to lucrative Medicare and Medicaid reimbursements.

As part of this transition, patients currently in the program will be referred to TransHealth, a nonprofit healthcare facility within Massachusetts.

In an official statement, Baystate Health clarified that suspending gender-affirming medication for those under 18, while still offering gender-affirming mental health counseling, reflects both ongoing evaluations of healthcare regulations and the system’s commitment to delivering quality care. They are working closely with impacted patients and families to ensure a seamless transition to suitable care providers.

The health system noted that close to 70% of its patients rely on Medicaid or Medicare, making it essential to maintain access to necessary health services for the community of over 800,000 residents in Western Massachusetts. They expressed a commitment to supporting families through this change while maintaining high standards of care.

This change is not isolated, as other health systems, such as NYU Langone Health, have also discontinued transgender programs for minors in response to the evolving regulatory landscape. The cessation of these services has generated criticism, with advocates describing the moves as harmful.

The discussion surrounding gender-affirming care for minors continues to unfold amid various legal and ethical considerations. Recently, some medical organizations suggested delaying gender-related surgeries until patients reach adulthood, citing concerns over the maturity and decision-making capabilities of younger patients.